Ligand Pharmaceuticals
Ligand Pharmaceuticals Inc is an American biopharmaceutical company enabling drug development through intellectual property monetization and licensing. The company acquires and licenses rights to early-stage through commercial biopharmaceutical assets and platforms such as Captisol. Main revenue drivers comprise royalty payments on commercialized partner drugs, technology licensing fees, development milestones, and Captisol material sales. Ligand Pharmaceuticals serves global pharmaceutical companies and biotechnology developers across North America, Europe, and Asia. The company occupies a unique market position by maintaining a diversified royalty portfolio without financing internal clinical trial execution. Headquartered in San Diego, California, Ligand Pharmaceuticals Inc is listed on the Nasdaq Stock Market.
12 of the funds FundTelligence covers report a position in Ligand Pharmaceuticals.
- Legal name
- Ligand Pharmaceuticals Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 12
Funds holding Ligand Pharmaceuticals
- Aberdeen North American Smaller Companies Fund — Abrdn · 2.9 % (largest positions only, September 2026)
- Indecap Guide Global Offensiv — Indecap · 2.08 % (full portfolio disclosed, June 2026)
- Nordea Global Small Cap Enhanced — Nordea Funds · 1.77 % (full portfolio disclosed, September 2026)
- Nordea Global Small Cap — Nordea Funds · 1.75 % (full portfolio disclosed, September 2026)
- Nordea BetaPlus Enhanced Global Sustainable Small Cap — Nordea Funds · 0.62 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.6 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.4 % (full portfolio disclosed, October 2026)
- Schroder ISF Global Convertible Bond — Schroders · 0.11 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 12 funds holding it.